Time filter

Source Type

Shenyang, China

Han Y.,General Hospital of Shenyang Military Command | Xu B.,National Center for Cardiovascular Diseases | Xu K.,General Hospital of Shenyang Military Command | Guan C.,National Center for Cardiovascular Diseases | And 16 more authors.
Circulation: Cardiovascular Interventions | Year: 2016

Background - There are no reports on a large-scale randomized trial exploring optimal dual antiplatelet therapy (DAPT) duration after biodegradable polymer sirolimus-eluting stent implantation. We sought to report the outcomes of a randomized substudy of the prospective Evaluate Safety and Effectiveness of the Tivoli DES and the Firebird DES for Treatment of Coronary Revascularization (I-LOVE-IT 2) trial. Methods and Results - In the prospective noninferiority randomized I-LOVE-IT 2 trial, 1829 patients allocated to the biodegradable polymer sirolimus-eluting stent group were also randomized to receive either 6-month (n=909) or 12-month DAPT (n=920). The primary end points of this noninferiority substudy were 12-month target lesion failure (composite of cardiac death, target vessel myocardial infarction or clinically indicated target lesion revascularization), and the major secondary end points were 12-month net adverse clinical and cerebral events (composite of all-cause death, all myocardial infarction, stroke, or major bleeding [Bleeding Academic Research Consortium type ≥3]). The 12-month target lesion failure in 6-month DAPT group was comparable with the 12-month DAPT group (6.8% versus 5.9%; difference and 95% confidence interval, 0.87% [-1.37% to 3.11%], P for noninferiority=0.0065). Further follow-up at 18 months showed that incidence of target lesion failure and net adverse clinical and cerebral events were similar between the 2 groups (7.5% versus 6.3%, log-rank P=0.32; 7.8% versus 7.3%, log-rank P=0.60; respectively), as well as their individual end point components. Conclusions - This study indicated noninferiority in safety and efficacy of 6-month versus 12-month DAPT after implantation of a novel biodegradable polymer sirolimus-eluting stent. © 2016 American Heart Association, Inc. Source

Guan D.,Shenyang University | Zhong Y.,Northeastern University China | Feng J.,Northeastern University China | Xu L.,Northeastern University China | Wang L.,Shengjing Hospital
2012 IEEE International Conference on Information and Automation, ICIA 2012 | Year: 2012

The quality analysis of pathological voice is not only a kind of objective evaluation for the human voice, but also an objective evidence for the application of voice disease diagnosis and the judgment of therapy. In this paper, the pathological voice quality analysis system is composed of five parts, which are voice recording, voice signal processing, and extraction of voice characteristic parameters, choice of these features and evaluation of voice quality. Firstly, this paper gives a brief introduction to the pathological voice quality analysis's background and purpose. Besides, it also details some methods of voice signal processing. For detection of voice period, vague fundamental frequency of voice is extracted firstly by using Fourier transform, and then the accurate detection of the voice period through EGG and wavelet transformation is performed. This method of period detection is highly accurate and practicable. Based on the period of voice, many features of voice such as the fundamental frequency, frequency perturbation, and amplitude perturbation can be extracted. This database is built by collecting healthy and pathological voice samples from Shengjing Hospital and related references. After analyzing the collected voice signals, the result shows that the pathological voice quality analysis system has the well evaluation performance in the practical application. These evaluation results reflect the quality of voice signal and can be used to assistant judge the treatment of voice disease and the recovery condition of treatment. © 2012 IEEE. Source

Guo Y.,Liaoning Medical University | Ma J.,Shengjing Hospital | Zheng Y.,Liaoning Medical University | Li L.,Liaoning Medical University | And 4 more authors.
Oncology Letters | Year: 2016

Overexpression of Aurora A kinase occurs in certain types of cancer, and therefore results in chromosome instability and phosphorylation-mediated ubiquitylation and degradation of p53 for tumorigenesis. The high-risk subtype human papillomavirus (HPV)16 early oncoprotein E6 is a major contributor inducing host cell immortalization and transformation through interaction with a number of cellular factors. In the present study, co-immunoprecipitation, glutathione S-transferase pull-down and immunostaining were used to show that HPV16 E6 and Aurora A bind to each other in vivo and in vitro. Western blotting and reverse transcription-polymerase chain reaction were used to reveal that HPV16 E6 inhibited cell apoptosis by stabilizing Aurora A expression. The present study may report a new mechanism for the involvement of HPV16 E6 in carcinogenesis, as HPV16 E6 elevates Aurora A expression and the latter may be a common target for oncogenic viruses that result in cell carcinogenesis. © 2016, Spandidos Publications. All rights reserved. Source

Li W.,Shenyang University | Meng J.,Central University of Costa Rica | Li X.,Shenyang University | Hua H.,Shenyang University | And 5 more authors.
Human Vaccines and Immunotherapeutics | Year: 2012

The aim of this investigation is to look at whether MENK could improve antitumor effect of CD8+ T cell elicited by BMDCs. We investigated the effects of MENK on the differentiation, maturation, and functions of murine BMDC loaded with Rac-1 antigens (RG) and CTL of tumor specific immune response elicited by the BMDC in vitro and in vivo. The production of cytokine IL-12 and TNF-α secreted by BMDCs in the presence of MENK was assayed with ELISA and key surface markers of CD40, CD86, CD83 and MHC-II on the BMDCs were analyzed with use of flow cytometry (FCM). In addition, the activities to induce CD8+ T cell proliferation, along with displayed cytotoxicity of the CD8+ T cells (CTL) by the BMDCs after treatment with MENK were determined with use of FCM as well as MTS. Our results indicated that MENK induced phenotypic and functional maturation of BMDC loaded with RG antigen, as evidenced by higher level of expression of key surface markers and more production of cytokines. Subsequently, the BMDC activated by MENK intensified immune responses mounted by CTL, resulting in stronger antitumor activity. Our results suggest that MENK could be working as an effective immune adjuvant in vaccine preparation for cancer fight and other immune related diseases. We concluded that MENK could be a positive immune modulator in the improved functions of BMDCs loaded with antigen as well as in CD8+ T cell mediated anti-tumor responses. © 2012 Landes Bioscience. Source

Zhao C.,Shenyang University | Bu X.,Shengjing Hospital
Histology and Histopathology | Year: 2012

Aberrant promoter methylation and subsequent silencing of cancer-related genes has been recognized as an important pathway involved in gastric carcinogenesis. In fact, several factors are believed to contribute to its induction in gastric epithelia, including aging, diet, chronic inflammation and infection of Helicobacter pylori (H. pylori) and Epstein-Barr virus (EBV). However, the underling mechanisms are not completely identified, despite the belief that increased expression or activity of DNA methyltransferases (DNMTs), or decreased demethylation activity may contribute to the excessive methylation. A great number of genes with promoter methylation have been observed in gastric cancer (GC), among which p16INK4A (p16), Mut L homologue 1 (MLH1), Epithelial-cadherin (Ecadherin), Runt-related transcription factor 3 (RUNX3), adenomatous polyposis coli (APC), O(6)- methylguanine-DNA methyltransferase (MGMT), Ras association domain family 1A (RASSF1A) and Deathassociated protein kinase (DAPK) have been extensively studied. Unlike the distinct methylation characterization in single genes, methylation analysis of multiple genes may provide more information in risk prediction, early detection, prognosis assessment and chemotherapy choice for GC. Specifically, particular monitoring and screening should be performed on those over 45 years old, with precancerous gastric disease or infection of H. pylori or EBV. As an alternative to tumor tissues, methylation detection in patient sera or gastric washes may also be used in risk prediction and early detection. However, what still poses a great challenge as well as a puzzle is the determination of the very genes that should be used in methylation analysis. Because epigenetic alterations are normally reversible, drugs or chemical compounds with demethylating activity, such as 5-aza- 2'-deoxycytidine (5-aza-dC) could be used in the treatment of patients with multiple gene methylation. In view of the adverse effects of 5-aza-dC, DNMT-targeted strategy has been proposed and may prove to be more effective than demethylating agents. Source

Discover hidden collaborations